Overview:
This systematic review analyzed published studies on the combined use of intranasal corticosteroids (INCS) and oxymetazoline for treating chronic rhinitis—including both allergic and nonallergic types. The goal was to evaluate the safety and efficacy of this combination, particularly in relation to concerns about oxymetazoline-induced rebound congestion (rhinitis medicamentosa).
The Takeaways:
-
The combination of intranasal corticosteroids and oxymetazoline resulted in significantly greater improvement in nasal congestion compared to either agent alone or placebo.
-
Patients using the combination therapy had a higher increase in nasal volume (mean 15.8 ± 1.1 ml) compared to placebo (12.1 ± 0.9 ml) or oxymetazoline alone (12.4 ± 0.8 ml), indicating better nasal airway patency.
-
The review found no evidence of rhinitis medicamentosa with combination use, suggesting it is safe for extended use beyond the traditional 3–5 day decongestant limit.
Why It Matters:
Oxymetazoline is a powerful decongestant, but its solo use is often restricted due to risks of rebound congestion. This review shows that combining oxymetazoline with a corticosteroid allows for more effective and sustained symptom relief without triggering rhinitis medicamentosa. It offers a safer, longer-term option for patients with chronic rhinitis.
The Link to Allermi:
Allermi’s personalized nasal sprays often combine low-dose oxymetazoline with intranasal corticosteroids to maximize symptom control while minimizing risks. This systematic review provides strong support for Allermi’s approach—delivering aggressive, targeted decongestant therapy in a safe, controlled way that avoids rebound congestion and improves patient outcomes.
For more details, refer to the full study: Intranasal corticosteroid and oxymetazoline for chronic rhinitis: a systematic review
